@pandawan
Shenogen has developed a globally patented synthetic small molecule compound. The compound has shown effectiveness in substituting IL-2 and other cytokines. This leads to the improvement in the in vitro expansion efficiency of engineered T cells. #QMPortfolio
0 reply
0 recast
0 reaction